Article

Allergan enters definitive merger agreement with Inamed

Allergan Inc. and Inamed Corp. entered a definitive agreement and plan of merger. For each outstanding common share of Inamed, Allergan will exchange either $84 in cash or 0.8498 of a share of Allergan common stock. The exchange began on Nov. 21, 2005, and will expire Jan. 9, 2006 (subject to extension or early termination).

"The signing of the merger agreement by both parties marks a significant milestone in the process of combining the two companies and delivering on our vision to create a leading world franchise in the high-growth medical aesthetics arena," said David E.I. Pyott, Allergan's chairman of the board, president, and chief executive officer.

Inamed also entered into a termination agreement with Ipsen Ltd., so that Ipsen will retain its rights to botulinum toxin type A (Reloxin). Through the agreement, both companies release each other of distribution obligations for the product.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.